Research
Hormonal
Tirzepatide use is associated with a risk of idiosyncratic acute liver injury, characterized by severe hepatotoxicity and coagulopathy, which resolves upon discontinuation of the drug.
If you are using tirzepatide for weight loss, do not skip liver function tests. While liver injury is rare, it can be severe and rapid. Report any persistent abdominal pain, vomiting, or yellowing of skin/eyes immediately. The drug should be stopped if liver enzymes rise significantly.
LimitedSupportsLOW confidence
This case underscores the need for further research and frequent following of liver enzymes when using tirzepatide for weight loss.
Why this rating
Based on a single case report; lacks statistical power but provides strong temporal and mechanistic plausibility.
Source
Tirzepatide-related acute liver injury
Irrum Abdullah et al. · European Journal of Case Reports in Internal Medicine · 2024
DOI 10.12890/2024_004813
case_report · n=1Cited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →